Boehringer Ingelheim and Veeva Systems have announced the launch of Boehringer’s One Medicine Platform, powered by the successful implementation of Veeva Development Cloud. They first announced the One Medicine collaboration in March 2022. The unified platform brings together data and processes across clinical, regulatory, and quality, enabling Boehringer to streamline its product development. With the One Medicine Platform, Boehringer can seamlessly connect data across functions, optimize trial efficiency and collaboration with research sites, and accelerate the delivery of new medicines to treat currently incurable diseases.
Health Technology Insights: Suvoda Unveils Sofia, an AI Assistant to Streamline Clinical Trials
“Together with Veeva, Boehringer has advanced its approach to clinical trials and is fulfilling our pledge to accelerate the delivery of innovative, life-transforming treatments to patients across the world,” said Oliver Fink, head of learning, process and digitalization at Boehringer Ingelheim. “Veeva Development Cloud provides the technology foundation for Boehringer’s One Medicine Platform, giving our teams the flexibility to design and run studies with greater speed, efficiency, and compliance.”
Health Technology Insights: Freed Raises $30 Million Series A to Ease Clinicians’ Admin Burdens With AI
“By connecting clinical, regulatory, and quality on Veeva Development Cloud, Boehringer unifies data and breaks down silos across teams to accelerate drug development and approvals,” said Rik van Mol, senior vice president, Veeva Development Cloud. “This is an exciting milestone toward realizing Veeva and Boehringer’s shared mission to advance the use of data and technology to modernize clinical trials and deliver better patient outcomes.”
Veeva Development Cloud is the technology foundation for product development, bringing together clinical, quality, regulatory, and safety applications to simplify end-to-end business processes and deliver process excellence.
Health Technology Insights: Lumata Health Raises $23 Million Series B to Expand Vision-Saving Care Access
To participate in our interviews, please write to our HealthTech Media Room at news@intentamplify.com
Source – prnewswire
